Healthcare Industry News: Consensus Interferon
News Release - January 14, 2008
Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant PharmaceuticalsCRANBERRY TOWNSHIP, Pa., Jan. 14 (HSMN NewsFeed) -- Three Rivers Pharmaceuticals, LLC finalized acquisition of the hepatitis C drug Infergen from Valeant Pharmaceuticals International (NYSE: VRX ). Valeant is receiving $91 million from Three Rivers for the procurement.
"Adding Infergen to our growing portfolio is very exciting," said Donald J. Kerrish, RPh, Three River's president and chief executive officer. "This purchase is only a beginning for Three Rivers' continuous strategy to increase its product offerings through product acquisition and internal product development of pharmaceutical therapies."
Infergen, or Consensus Interferon, is a bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched in the United States in 1997. It is currently indicated as monotherapy for the treatment of adult patients suffering from chronic hepatitis C viral infections with compensated liver disease and is dosed three times per week.
Important Safety Information
Physicians and patients can obtain additional prescribing information regarding Infergen, including the product's safety profile and the box warning for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and infectious disorders, by visiting www.infergen.com.
About Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals is a privately held company headquartered in Cranberry Township, Pennsylvania and focuses on specialized therapies including hepatitis C therapies. Three Rivers is the first drug company to focus on the needs of the emerging specialty market. With its unique experience and understanding of the complex challenges of treating chronic, difficult diseases, Three Rivers is a valuable partner in the healthcare community.
The company's mission is to develop, manufacture, and market the highest quality branded and generic drug products for patients with serious diseases. Three Rivers Pharmaceuticals focuses on specialized therapies because of our extensive knowledge and experience in this area. More information about the company can be found at www.3riverspharma.com.
Source: Three Rivers Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.